Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Brickell Biotech announces publication of HDSM-Ax scale validation results » 08:10
04/15/21
04/15
08:10
04/15/21
08:10
BBI

Brickell Biotech

/

+

Brickell Biotech…

Brickell Biotech announced that results from a Phase 2b study evaluating the use of Hyperhidrosis Disease Severity Measure-Axillary, or HDSM-Ax, Brickell's proprietary patient reported outcome scale, to measure primary axillary hyperhidrosis, or AHH, severity were published in the peer-reviewed Journal of Drugs in Dermatology. The article, entitled "Hyperhidrosis Disease Severity Measure-Axillary: Evaluation of Measurement Performance," can be accessed online here. The psychometric analyses conclude that HDSM-Ax is a "well-defined and reliable measure of primary AHH severity that is expected to improve the assessment of axillary hyperhidrosis treatment effects compared to pre-existing scales, such as the Hyperhidrosis Disease Severity Scale," the company said. The analyses determine that a 1-point change in HDSM-Ax severity score represents a clinically meaningful change in AHH severity.

ShowHide Related Items >><<
BBI Brickell Biotech
/

+

BBI Brickell Biotech
/

+

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
  • 23
    Oct
  • 18
    Jun
Wednesday
Earnings
Theratechnologies reports Q1 EPS (7c) vs. (6c) last year » 07:41
04/14/21
04/14
07:41
04/14/21
07:41
THTX

Theratechnologies

$3.81 /

-0.15 (-3.79%)

Reports Q1 revenue…

Reports Q1 revenue $15.43M vs. $15.72M last year. "Theratechnologies is at a unique point in its evolution, and we have a tremendous opportunity ahead of us," said Paul Levesque, President and CEO at Theratechnologies. "We are particularly pleased with the swift advancement of our Phase 1 oncology program, which has dosed its first patient, and the continued progress we have made toward advancing our Phase 3 trial in NASH. We believe we are well-positioned for growth when we begin to emerge from the COVID-19 pandemic. Inline with these efforts is our continued focus on strengthening our business with the addition of key talent and resources. While first-quarter revenues were relatively flat year-over-year, we believe that we have aligned our organization to provide an optimal landscape to further validate and drive value for our commercial and R&D opportunities."

ShowHide Related Items >><<
THTX Theratechnologies
$3.81 /

-0.15 (-3.79%)

THTX Theratechnologies
$3.81 /

-0.15 (-3.79%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.81 /

-0.15 (-3.79%)

Over a week ago
Conference/Events
Brickell Biotech to hold a conference call » 09:25
03/26/21
03/26
09:25
03/26/21
09:25
BBI

Brickell Biotech

$1.19 /

+0.02 (+1.72%)

Management holds a…

Management holds a conference call to provide an overview of Hyperhidrosis (excessive sweating) on March 26 at 10 am. Webcast Link

ShowHide Related Items >><<
BBI Brickell Biotech
$1.19 /

+0.02 (+1.72%)

BBI Brickell Biotech
$1.19 /

+0.02 (+1.72%)

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
  • 23
    Oct
  • 18
    Jun
Conference/Events
Brickell Biotech to hold a conference call » 04:55
03/26/21
03/26
04:55
03/26/21
04:55
BBI

Brickell Biotech

$1.19 /

+0.02 (+1.72%)

Management holds a…

Management holds a conference call to provide an overview of Hyperhidrosis (excessive sweating) on March 26 at 10 am. Webcast Link

ShowHide Related Items >><<
BBI Brickell Biotech
$1.19 /

+0.02 (+1.72%)

BBI Brickell Biotech
$1.19 /

+0.02 (+1.72%)

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
  • 23
    Oct
  • 18
    Jun
Hot Stocks
Theratechnologies announces first patient dosed in clinical trial of TH1902 » 07:33
03/24/21
03/24
07:33
03/24/21
07:33
THTX

Theratechnologies

$3.59 /

-0.32 (-8.18%)

Theratechnologies…

Theratechnologies announced that the first patient received a dose of TH1902, its lead peptide-drug conjugate for the treatment of sortilin positive solid tumors. "Despite the progress made in recent years in the field of oncology, many patients are unfortunately not responding to current treatments or do not tolerate them well. Targeting the sortilin receptor is an exciting and promising new approach for the potential treatment of cancer. Dosing the first patient with TH1902 brings us closer to a potential much needed new option in oncology," said Doctor Satish Shah, Medical Director, Gettysburg Cancer Center, and Doctor Tina Khair, Research Director, Gettysburg Cancer Center.

ShowHide Related Items >><<
THTX Theratechnologies
$3.59 /

-0.32 (-8.18%)

THTX Theratechnologies
$3.59 /

-0.32 (-8.18%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.59 /

-0.32 (-8.18%)

Hot Stocks
Theratechnologies presents data demonstrating Tesamorelin effect on liver fat » 13:52
03/21/21
03/21
13:52
03/21/21
13:52
THTX

Theratechnologies

$3.51 /

+0.1 (+2.93%)

Theratechnologies…

Theratechnologies announced that new data, demonstrating the positive effect of tesamorelin on the circulation of immune activation markers associated with liver inflammation, was presented at The Endocrine Society's annual meeting, ENDO 2021. The data comes from a sub-analysis of a double-blind, randomized, 12-month investigator-initiated trial studying the effect of tesamorelin on liver fat in 61 people infected with HIV with nonalcoholic fatty liver disease. The sub-analysis concludes that treatment with tesamorelin for 12 months decreased circulating markers of T-cell and monocyte/macrophage activity. A corresponding downregulation of immune pathways in the liver was also observed. These conclusions suggest that treatment with tesamorelin may contribute to better regulated immune activation in a population with metabolic dysregulation and systemic inflammation. The company plans to initiate the Phase 3 clinical trial by the end of the third quarter of calendar year 2021. The timing of the trial initiation and the final number of patients enrolled are dependent upon any adjustments to the protocol and trial design as recommended by the FDA and EMA. The company has retained the services of a global, large-scale contract research organization, or CRO, with experience in implementing large and late-stage clinical trials to assist with the execution of its Phase 3 clinical trial in NASH.

ShowHide Related Items >><<
THTX Theratechnologies
$3.51 /

+0.1 (+2.93%)

THTX Theratechnologies
$3.51 /

+0.1 (+2.93%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.51 /

+0.1 (+2.93%)

Conference/Events
Brickell Biotech to hold a conference call » 15:31
03/19/21
03/19
15:31
03/19/21
15:31
BBI

Brickell Biotech

$1.26 /

+0.0299 (+2.43%)

Management holds a…

Management holds a conference call to provide an overview of Hyperhidrosis (excessive sweating) on March 26 at 10 am. Webcast Link

ShowHide Related Items >><<
BBI Brickell Biotech
$1.26 /

+0.0299 (+2.43%)

BBI Brickell Biotech
$1.26 /

+0.0299 (+2.43%)

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
  • 23
    Oct
  • 18
    Jun
Over a month ago
Syndicate
Brickell Biotech files $150M mixed securities shelf  16:30
03/09/21
03/09
16:30
03/09/21
16:30
BBI

Brickell Biotech

$1.23 /

+0.095 (+8.37%)

 
ShowHide Related Items >><<
BBI Brickell Biotech
$1.23 /

+0.095 (+8.37%)

BBI Brickell Biotech
$1.23 /

+0.095 (+8.37%)

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
  • 23
    Oct
  • 18
    Jun
Hot Stocks
Brickell Biotech to host KOL webinar on the hyperhidrosis market » 08:08
03/05/21
03/05
08:08
03/05/21
08:08
BBI

Brickell Biotech

$1.17 /

+ (+0.00%)

Brickell Biotech…

Brickell Biotech announced that it will host a key opinion leader webinar on the hyperhidrosis market on Friday, March 26, 2021 at 10:00 am EDT. This webinar will feature presentations by hyperhidrosis KOLs Adam Friedman, MD, The George Washington University School of Medicine & Health Sciences, and Joel L. Cohen, MD, AboutSkin Dermatology, who will provide an overview of hyperhidrosis through both the eyes of a patient and diagnosing clinician. Both dermatologists will discuss the unmet need that exists in hyperhidrosis, the current treatment landscape, and the negative quality of life impacts experienced by both pediatric and adult patients. Drs. Friedman and Cohen will be available to answer questions following the formal presentations. Robert Brown, CEO of Brickell, also will provide a corporate update. Brickell's lead investigational product candidate, sofpironium bromide, is a new chemical entity that is currently being evaluated in a pivotal Phase 3 clinical program in the U.S. as a potential best-in-class therapy for treatment of primary axillary hyperhidrosis. Brickell expects to report topline data from this Phase 3 clinical program in the fourth quarter of 2021.

ShowHide Related Items >><<
BBI Brickell Biotech
$1.17 /

+ (+0.00%)

BBI Brickell Biotech
$1.17 /

+ (+0.00%)

09/25/20 Lake Street
Approval in Japan validating for Brickell Biotech, says Lake Street
08/28/20 Lake Street
Brickell Biotech initiated with a Buy at Lake Street
08/25/20 Oppenheimer
Brickell Biotech initiated with an Outperform at Oppenheimer
  • 23
    Oct
  • 18
    Jun
Hot Stocks
Theratechnologies receives fast track designation from FDA for TH1902 » 07:34
02/04/21
02/04
07:34
02/04/21
07:34
THTX

Theratechnologies

$2.33 /

+0.06 (+2.64%)

Theratechnologie…

Theratechnologie announced that the FDA has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy. "Receiving fast track designation for TH1902 at this early stage of development is a significant recognition for our SORT1+ Technology and further supports the future development of TH1902. The designation, which applies to all solid tumours expressing sortilin, also highlights the broad applicability and immense medical need for innovative, targeted, and potentially more effective and better-tolerated therapies for cancer," said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.

ShowHide Related Items >><<
THTX Theratechnologies
$2.33 /

+0.06 (+2.64%)

THTX Theratechnologies
$2.33 /

+0.06 (+2.64%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$2.33 /

+0.06 (+2.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.